Markets
Bill Ackman
Bill Ackman (Sylvain Gaboury, Patrick McMullan/Getty Images)

Bill Ackman’s pricey IPO plan

Pershing Square’s fundraising efforts need to bear fruit for this valuation to make sense

Jack Raines

Bill Ackman made headlines this morning after The Wall Street Journal reported that he is planning to take his investment fund, Pershing Square, public in late 2025 or early 2026. As a precursor to the planned IPO, Ackman is also selling a stake in the firm to investors in a funding round that will value Pershing Square at approximately $10.5B.

It’s rare for a hedge fund to IPO in the US because the US Investment Company Act of 1940 prevents investing groups from charging retail investors expensive performance fees, such as the “2 and 20” that is common for hedge funds. Hedge funds can, however, charge “qualified purchasers” (generally high-net worth clients or institutions) higher fees, which is why hedge funds are typically private.

However, Bill Ackman isn’t looking to take a “hedge fund” public. To quote the Journal piece (emphasis ours):

Pershing Square has told potential investors to compare it to asset managers like Brookfield Asset Management and Blue Owl Capital rather than hedge funds. Brookfield’s market value is about $15 billion; it has more than $925 billion in assets under management. Blue Owl’s market value is about $28 billion and it manages more than $174 billion.

Basically, Ackman isn’t looking to take a specific investment vehicle public. He wants to IPO the holding company that happens to own several investment vehicles, which… kind of makes sense?

As of their February 2024 annual report, Pershing Square had $18.2B in assets under management (AUM), consisting of the following:

  • $14.6B in a closed-end Europe fund (PSH), which is listed on the Amsterdam and London exchanges

  • $1.6B in an investment vehicle that it used to purchase a stake of United Music Group

  • $2B in traditional hedge funds

Pershing listed its largest fund in the European markets in 2014 to skirt US regulations regarding fees: while they couldn’t charge high performance fees on a publicly traded US-listed fund, they can (and do) charge a 1.5% management fee and a 16% performance fee on their European fund.

The planned IPO would sell stakes in the parent entity controlling the funds, which wouldn’t charge high management fees, rather than a specific investment vehicle. While The Wall Street Journal reported that the $10.5B valuation looks high, (for context, Blue Owl Capital is worth $28B with $174B in AUM), the firm justified its valuation by explaining that it will soon manage much more money. From the Journal piece:

The firm justified its rich valuation to investors by explaining that it expects to manage considerably more money, and eventually earn more in fees, after Pershing Square U.S.A. and other funds launch, people familiar with the matter said.

In February, Ackman announced plans to launch a $10 billion US-based closed-end fund which, importantly, would not charge a performance fee, and just a flat 2% management fee, keeping it within US regulations. 

Additionally, Pershing also received SEC approval to raise a multi-billion dollar “special-purpose acquisition rights company,” or SPARC, to take a private company public, which would further increase its AUM.

Why is Ackman now prioritizing the American market after a decade with most of his firm’s capital in Europe? One reason is that Pershing’s Europe-listed fund is trading at a ~27% discount to its net asset value (NAV), meaning that the price per share of its fund is worth 27% less than the value of its underlying assets. If Pershing’s European fund traded at a premium to its NAV, Pershing could issue new shares and raise money until the price per share matched the underlying assets. With its share price at a discount, however, any capital raise in Europe would be below the fund’s intrinsic value.

While Pershing’s $10 billion valuation feels high for the firm right now, that number could look more reasonable in the future depending on the company’s ability to raise funds for its new US closed-end fund, its SPARC, and any other ventures that Ackman may have up his sleeve.

More Markets

See all Markets
markets

FDA says it will take “decisive steps” against GLP-1 compounders, HHS refers Hims to DOJ for investigation

The Food and Drug Administration said it would take "decisive steps" to restrict GLP-1 compounding, a day after Hims & Hers announced that it would sell copies ofNovo Nordisk’sWegovy pill.

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

The FDA specifically called out Hims in the announcement. Additionally, Department of Health and Human Services' General Counsel Mike Stuart said in a post on X on Friday he has referred Hims to the Department of Justice "for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions."

In a statement, Hims said the company "has always operated with a deep commitment to the safety and best interests of consumers and in compliance with applicable law."

"We have a long history of successfully working with regulators, and look forward to continuing to engage with the FDA to ensure safe access to affordable healthcare," they said.

This marks a significant shift in tone from the FDA, which has done little to prevent companies like Hims from marketing copies of Novo's lucrative weight loss drugs.

Shares of Hims fell 14% after hours. The stock had already taken a hit after FDA Commissioner Marty Makary said in an X post on Thursday that the agency would “take swift action against companies mass-marketing illegal copycat drugs.”

Airlines rise, continuing their volatile 2026, as US-Iran talks may foreshadow some oil supply relief

Airline stocks are surging on Friday, as the market appears to be pricing in some medium-term oil pricing relief following talks between the US and Iran. Iranian officials referred to the meeting as “a good beginning.”

Shares of budget carriers, which have tighter margins and are more sensitive to fluctuations in fuel costs, are leading the surge. Frontier Airlines and Allegiant up more than 13%, while major airlines like United Airlines, American Airlines, and Delta Air Lines are also up at least 6%. JetBlue and Alaska Air are similarly up about 6%.

The market more broadly is rebounding on Friday, with the S&P 500 up 1.6% and bitcoin recovering some of this week’s losses.

Airlines have been volatile to start 2026 amid geopolitical tensions, varying annual forecasts, and the impact of winter storms.

markets

The AI supply chain is soaring thanks to Amazon’s capex budget

If tech companies are going to spend way more than expected on capex, well, that means other companies are poised to benefit from that massive spending spree.

Amazon’s plan for $200 billion in business investment this year was the exclamation point to end a reporting period that saw every Magnificent 7 hyperscaler that provides guidance offer a 2026 capex budget well above what Wall Street had anticipated.

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

Here’s a look at the different parts of the supply chain that are soaring on the persistent demand for, and seeming scarcity of, AI compute:

markets

For memory chips, the “parabolic price hike” is continuing to ramp higher

The remarkable run-up in prices for memory chips continued into early February, analysts at Bernstein Research say, driven largely by data center demand from hyperscalers and cloud service providers (CSP).

Prices for NAND flash memory wafers — a type of memory used in devices, as it retains data even when powered down — soared 35% between the end of 2025 and February 2.

Spot prices for DRAM — ubiquitous short-term data storage chips — jumped about 28% in that period. But that massively understates the remarkable shift in pricing for what were long seen as commodity tech hardware inputs. DRAM prices are more than 2,000% over the last year, while NAND prices are up more than 600% in that period.

The ongoing momentum provides still more support for memory chip plays like Micron and Sandisk, which have been big market winners in recent months.

In a note published earlier this week, Bernstein Research analysts wrote:

“The parabolic price hike continued in Jan. Indicated price increase for 1QCY26 is much stronger than we expected and we hence see upside to our near term memory pricing projection. Unrelenting CSP demand remained the main driver. PC and Mobile demand hasn’t been destroyed yet because of lean inventory & pull-forward purchase. Going forward price hike is expected to continue but likely at a slower rate, as PC and Mobile demand should contract meaningfully this year. Price however may stay elevated throughout this year, supported by CSP demand.”

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.